Drug
Cariprazine
Cariprazine: highest development phase Phase 3, developed by AbbVie, Gedeon Richter. 14 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie, Gedeon Richter
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cariprazine NCT05439616 | Phase 3 | Autism Spectrum Disorder |
| Cariprazine NCT01715805 | Phase 3 | Major Depressive Disorder |
| Cariprazine NCT03817502 | Phase 3 | Schizophrenia |
| Cariprazine NCT01412060 | Phase 3 | Schizophrenia |
| Cariprazine NCT01058096 | Phase 3 | Bipolar Disorder |
| Cariprazine NCT01104766 | Phase 3 | Schizophrenia |
| Cariprazine NCT01059539 | Phase 3 | Bipolar I Disorder |
| Cariprazine NCT01104779 | Phase 3 | Schizophrenia |
| Cariprazine NCT00694707 | Phase 2 | Schizophrenia |
| Cariprazine NCT01396447 | Phase 2 | Depression, Bipolar |
| Cariprazine (RGH-188) NCT00488618 | Phase 2 | Bipolar Disorder |
| Cariprazine NCT01469377 | Phase 2 | Major Depressive Disorder |
| Cariprazine NCT00839852 | Phase 2 | Schizophrenia |
| cariprazine NCT00852202 | Phase 2 | Bipolar Depression |
Latest
No recent events.
Follow Cariprazine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.